MedTrace Logo

Exploratory Study on the Safety, Tolerability, and Pharmacodynamics of IMB-1018972 in Subjects With Angina Due to Obstructive Coronary Artery Disease (IMPROVE-Ischemia)

NCT04826172 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2024-04-23

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and tolerability of IMB-1018972 in subjects with obstructive CAD and inducible ischemia.

Conditions

Interventions

DRUG

IMB-1018972

Modified release (MR) oral tablet

DRUG

Placebo

Matching oral tablet

Sponsors & Collaborators

  • Imbria Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Medical Monitor, MD · Imbria Pharmaceuticals, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-23
Primary Completion
2023-09-21
Completion
2023-09-21
FDA Drug
Yes

Countries

  • Denmark
  • Finland
  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04826172 on ClinicalTrials.gov